PMID- 32390401
OWN - NLM
STAT- MEDLINE
DCOM- 20210128
LR  - 20210128
IS  - 1433-6510 (Print)
IS  - 1433-6510 (Linking)
VI  - 66
IP  - 5
DP  - 2020 May 1
TI  - The Role of Resolvin D1 in the Differential Diagnosis of the Cholangiocarcinoma 
      and Benign Biliary Diseases.
LID - 10.7754/Clin.Lab.2020.200212 [doi]
AB  - BACKGROUND: The discrimination of malignant biliary strictures from benign 
      biliary diseases (BBDs) is challenging and complicated. We aimed to investigate 
      whether Resolvin D1 (RvD1) would aid in the discrimination of cholan-giocarcinoma 
      (CCA) from BBDs. METHODS: Thirty-one patients with CCA, 27 patients with BBD, and 
      30 healthy controls were enrolled in this cross-sectional study. The diagnosis of 
      CCA was based on results obtained from abdominal USG, MRCP, abdominal CT, 
      endosonography, and tumor markers, including CEA and CA 19-9. Histopathological 
      evaluation was performed in the majority of patients, and the final diagnosis was 
      based on surgery or biopsy results. RvD1, CEA, and CA 19-9 were analyzed in all 
      patients with CCA and BBD. RESULTS: RvD1 was significantly lower in those with 
      CCA compared to patients with BBD and healthy controls. In addition, CEA and Ca 
      19-9 levels were significantly higher in the CCA group than the BBD group (p < 
      0.001). RvD1 concentration, CA 19-9 concentration, and total bilirubin level were 
      found to be correlated with tumor stage (r = -0.702, 0.390, and 0.569, 
      respectively). ROC curve analysis revealed that an RvD1 concentration of < 380 
      ng/mL (AUC: 0.783, 95% CI: 0673 - 0.893, p < 0.001) and CA 19-9 concentration of 
      > 94.5 U/mL (AUC: 0.94, 95% CI: 0.898 - 0.998, p < 0.001) could be used to 
      discriminate patients with CCA from those with BBD. CONCLUSIONS: Resolvin D1 and 
      CA 19-9 levels might be used to effectively discriminate between BBD and CCA. 
      Moreover, both RvD1 and CA 19-9 levels are associated with the stage of CCA, 
      indicating that they may also be used in assessing disease progression.
FAU - Gul-Utku, Ozlem
AU  - Gul-Utku O
FAU - Karatay, Eylem
AU  - Karatay E
FAU - Ergul, Bilal
AU  - Ergul B
FAU - Kisa, Ucler
AU  - Kisa U
FAU - Erdin, Zuleyha
AU  - Erdin Z
FAU - Oguz, Dilek
AU  - Oguz D
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Clin Lab
JT  - Clinical laboratory
JID - 9705611
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CA-19-9 Antigen)
RN  - 0 (resolvin D1)
RN  - 25167-62-8 (Docosahexaenoic Acids)
SB  - IM
MH  - Aged
MH  - Bile Duct Diseases/*diagnosis
MH  - Bile Duct Neoplasms/*diagnosis
MH  - Biomarkers, Tumor/blood
MH  - CA-19-9 Antigen/blood
MH  - Cholangiocarcinoma/*diagnosis
MH  - Cross-Sectional Studies
MH  - Diagnosis, Differential
MH  - Docosahexaenoic Acids/*blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - ROC Curve
EDAT- 2020/05/12 06:00
MHDA- 2021/01/29 06:00
CRDT- 2020/05/12 06:00
PHST- 2020/05/12 06:00 [entrez]
PHST- 2020/05/12 06:00 [pubmed]
PHST- 2021/01/29 06:00 [medline]
AID - 10.7754/Clin.Lab.2020.200212 [doi]
PST - ppublish
SO  - Clin Lab. 2020 May 1;66(5). doi: 10.7754/Clin.Lab.2020.200212.